Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.57 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 9/20 | 0.49 |
| ▸ | MAOB | P27338 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | CALML3 | P27482 | 1/20 | 0.48 |
| ▸ | SDHA | P31040 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21634818 | 0.93 | MAOA (0.57) | MAOACYP2E1F10MAOBLMNA | |
| SCHEMBL21634822 | 0.93 | MAOA (0.57) | MAOACYP2E1F10MAOBLMNA | |
| SCHEMBL21634691 | 0.90 | MAOA (0.55) | MAOACYP2E1F10MAOBLMNA | |
| SCHEMBL5833650 | 0.85 | MAOB (0.65) | MAOACYP2E1F10MAOBLMNA | |
| SCHEMBL5833644 | 0.85 | MAOB (0.65) | MAOACYP2E1F10MAOBLMNA | |
| SCHEMBL6110851 | 0.85 | MAOA (0.62) | MAOACYP2E1F10MAOBLMNA | |
| SCHEMBL18409560 | 0.84 | MAOA (0.61) | MAOACYP2E1F10MAOBLMNA | |
| SCHEMBL21634693 | 0.83 | MAOA (0.54) | MAOACYP2E1F10MAOBLMNA | |
| SCHEMBL30817019 | 0.82 | MAOA (0.59) | MAOACYP2E1F10MAOBLMNA | |
| SCHEMBL30817028 | 0.82 | MAOA (0.59) | MAOACYP2E1F10MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12109203-B2 | Substituted oxazolidinones for the treatment of mammalian infections | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-10-08 | — | — | US | claimed |
| WO-2020021468-A1 | SUBSTITUTED OXAZOLIDINONES FOR THE TREATMENT OF MAMMALIAN INFECTIONS | CADILA HEALTHCARE LIMITED (IN) | 2020-01-30 | — | — | WO | claimed |
| US-12109203-B2 | Substituted oxazolidinones for the treatment of mammalian infections | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-10-08 | — | — | US | disclosed |
| WO-2020021468-A1 | SUBSTITUTED OXAZOLIDINONES FOR THE TREATMENT OF MAMMALIAN INFECTIONS | CADILA HEALTHCARE LIMITED (IN) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12109203-B2 | Substituted oxazolidinones for the treatment of mammalian infections | OXA1L, IL4I1, PEPD | MAOA 2648/4885CYP2E1 273/4885F10 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.